KR101994129B1 - 통증 치료를 위한 셀레콕시브 경구용 조성물 - Google Patents

통증 치료를 위한 셀레콕시브 경구용 조성물 Download PDF

Info

Publication number
KR101994129B1
KR101994129B1 KR1020177035928A KR20177035928A KR101994129B1 KR 101994129 B1 KR101994129 B1 KR 101994129B1 KR 1020177035928 A KR1020177035928 A KR 1020177035928A KR 20177035928 A KR20177035928 A KR 20177035928A KR 101994129 B1 KR101994129 B1 KR 101994129B1
Authority
KR
South Korea
Prior art keywords
celecoxib
composition
delete delete
stable
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177035928A
Other languages
English (en)
Korean (ko)
Other versions
KR20180012277A (ko
Inventor
안키트 바헤티
비제이 쿠마르 파드히
수프리타 바카다
라지브 싱 라그반시
Original Assignee
닥터 레디스 레보러터리즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 닥터 레디스 레보러터리즈 리미티드 filed Critical 닥터 레디스 레보러터리즈 리미티드
Publication of KR20180012277A publication Critical patent/KR20180012277A/ko
Application granted granted Critical
Publication of KR101994129B1 publication Critical patent/KR101994129B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020177035928A 2015-05-28 2016-05-27 통증 치료를 위한 셀레콕시브 경구용 조성물 Active KR101994129B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN2682/CHE/2015 2015-05-28
IN2682CH2015 2015-05-28
IN6614CH2015 2015-12-10
IN6614/CHE/2015 2015-12-10
PCT/US2016/034844 WO2016191744A1 (en) 2015-05-28 2016-05-27 Oral composition of celecoxib for treatment of pain

Publications (2)

Publication Number Publication Date
KR20180012277A KR20180012277A (ko) 2018-02-05
KR101994129B1 true KR101994129B1 (ko) 2019-06-28

Family

ID=56137539

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177035928A Active KR101994129B1 (ko) 2015-05-28 2016-05-27 통증 치료를 위한 셀레콕시브 경구용 조성물

Country Status (12)

Country Link
US (7) US9572819B2 (enExample)
EP (1) EP3302429A1 (enExample)
JP (1) JP6605047B2 (enExample)
KR (1) KR101994129B1 (enExample)
CN (3) CN117547528A (enExample)
AU (2) AU2016267685A1 (enExample)
CA (1) CA2987272C (enExample)
EA (1) EA038013B1 (enExample)
MX (1) MX384044B (enExample)
NZ (1) NZ737561A (enExample)
RU (1) RU2708254C2 (enExample)
WO (1) WO2016191744A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016191744A1 (en) * 2015-05-28 2016-12-01 Dr. Reddy's Laboratories Ltd. Oral composition of celecoxib for treatment of pain
RU2745196C2 (ru) 2016-05-27 2021-03-22 Др. Редди'С Лабораторис Лтд. Пероральная композиция целекоксиба для лечения боли
US11018667B2 (en) 2018-01-05 2021-05-25 Darfon Electronics Corp. Optical keyswitch
US11770123B2 (en) 2018-01-05 2023-09-26 Darfon Electronics Corp. Optical keyswitch comprising a keycap having a light transmission area and a keycap projection area projected on a circuit board
CN114681470A (zh) 2020-12-28 2022-07-01 雷迪博士实验室有限公司 治疗疼痛的方法
US11735379B2 (en) 2021-04-07 2023-08-22 Darfon Electronics Corp. Keyswitch assembly
US11721500B2 (en) 2021-04-07 2023-08-08 Darfon Electronics Corp. Keyswitch assembly and support mechanism thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047752A2 (en) 2002-11-26 2004-06-10 Transform Pharmaceuticals, Inc. Pharmaceutical formulations of celcoxib
WO2010150144A2 (en) 2009-06-25 2010-12-29 Wockhardt Research Centre Low dose pharmaceutical compositions of celecoxib

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69222847T3 (de) 1991-04-16 2005-09-15 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung einer festen dispersion
KR100263817B1 (ko) 1993-11-30 2000-08-16 윌리암스 로저 에이 염증치료용 치환 피라졸일벤젠술폰아미드
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5993858A (en) 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
BR9810866B1 (pt) 1997-07-29 2010-07-13 composição farmacêutica em uma forma de formulação auto-emulsificante para compostos lipofìlicos.
US6280770B1 (en) 1998-08-13 2001-08-28 Cima Labs Inc. Microemulsions as solid dosage forms for oral administration
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
CN1236813C (zh) 1998-12-11 2006-01-18 药品处理公司 水难溶性药物的自乳化组合物
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6057289A (en) 1999-04-30 2000-05-02 Pharmasolutions, Inc. Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
JP2004500358A (ja) * 1999-12-08 2004-01-08 ファルマシア　コーポレイション バイオアベイラビリティーが増加した固体状態のセレコキシブ
DE60016191T2 (de) * 1999-12-08 2005-12-22 Pharmacia Corp., Chicago Cyclooxygenase-2 hemmer enthaltende zusammensetzungen mit schnellem wirkungseintritt
MXPA02010259A (es) * 2000-04-18 2003-12-11 Pharmacia Corp Formulacion de accion rapida de un inhibidor selectivo de ciclooxigenasa-2.
US20080009467A1 (en) * 2000-05-01 2008-01-10 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
AR035642A1 (es) 2000-05-26 2004-06-23 Pharmacia Corp Uso de una composicion de celecoxib para el alivio rapido del dolor
AU3091802A (en) 2000-10-31 2002-05-15 Boehringer Ingelheim Pharma Oral dosage self-emulsifying formulations of pyranone protease inhibitors
JP2005500314A (ja) 2001-06-21 2005-01-06 ファイザー・プロダクツ・インク コレステロールエステル転送蛋白インヒビターの自己乳化性製剤
US20030073609A1 (en) * 2001-06-29 2003-04-17 Pinkerton Thomas C. Enhanced pharmacokinetic profile of intradermally delivered substances
US20050025791A1 (en) 2002-06-21 2005-02-03 Julius Remenar Pharmaceutical compositions with improved dissolution
IL164163A0 (en) 2002-04-09 2005-12-18 Pharmacia Corp Process for preparing a finely self-emulsifiable pharmaceutical composition
US6689382B2 (en) * 2002-05-15 2004-02-10 Procaps S.A. Soft shell gelatin capsules containing non-steroidal anti-inflammatories
US20050191343A1 (en) * 2003-11-26 2005-09-01 Shire Laboratories, Inc. Micellar systems useful for delivery of lipophilic or hydrophobic compounds
KR20090010953A (ko) 2006-03-28 2009-01-30 자블린 파머슈티칼스 인코포레이티드 저 복용량의 비-스테로이드성 항염증성 약물 및 베타-사이클로덱스트린 제형
EP1961412A1 (en) 2006-12-27 2008-08-27 LEK Pharmaceuticals D.D. Self-microemulsifying drug delivery systems
WO2008115572A1 (en) 2007-03-21 2008-09-25 Theraquest Biosciences, Inc. Methods and compositions of nsaids
WO2009063367A1 (en) * 2007-11-15 2009-05-22 Pfizer Products Inc. Dosage forms comprising celecoxib providing both rapid and sustained pain relief
EP2311446A1 (en) * 2009-10-16 2011-04-20 Laboratorios Del. Dr. Esteve, S.A. Compositions comprising Tramadol and Celecoxib in the treatment of pain
EP2340819A1 (en) * 2009-12-23 2011-07-06 Laboratorios Del. Dr. Esteve, S.A. Compositions comprising venlafaxine and celecoxib in the treatment of pain
WO2012037328A2 (en) * 2010-09-17 2012-03-22 Maine Natural Health, Inc. Compositions containing omega-3 oil with an anti-inflammatory agent and uses thereof
KR101413846B1 (ko) * 2012-04-12 2014-06-30 주식회사 종근당 ４－［５－（４－메칠페닐）－３－（트리플루오로메칠）피라졸－１－일］벤젠술폰아미드 화합물 함유 액상 조성물
KR101455901B1 (ko) * 2012-05-04 2014-11-03 성균관대학교산학협력단 세레콕시브 및 폴록사머를 포함하는 공융 혼합물
KR20140100170A (ko) * 2013-02-05 2014-08-14 에스케이케미칼주식회사 셀레콕시브 경구투여용 조성물
MX349193B (es) 2013-08-27 2017-07-18 Alparis Sa De Cv Capsula con contenido liquido con un antiinflamatorio.
US9446056B2 (en) * 2014-02-11 2016-09-20 Dr. Reddy's Laboratories Ltd. Parenteral compositions of celecoxib
US20150342893A1 (en) * 2014-05-29 2015-12-03 Sigmoid Pharma Limited Celecoxib formulations useful for treating colorectal cancer
WO2016191744A1 (en) * 2015-05-28 2016-12-01 Dr. Reddy's Laboratories Ltd. Oral composition of celecoxib for treatment of pain
WO2016196085A1 (en) * 2015-05-29 2016-12-08 Kiel Laboratories, Inc. Liquid formulations of celecoxib for oral administration

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047752A2 (en) 2002-11-26 2004-06-10 Transform Pharmaceuticals, Inc. Pharmaceutical formulations of celcoxib
WO2010150144A2 (en) 2009-06-25 2010-12-29 Wockhardt Research Centre Low dose pharmaceutical compositions of celecoxib

Also Published As

Publication number Publication date
US10376527B2 (en) 2019-08-13
RU2017144574A (ru) 2019-06-28
CN107847437B (zh) 2024-03-26
US20190224219A1 (en) 2019-07-25
US20220241298A1 (en) 2022-08-04
JP6605047B2 (ja) 2019-11-13
US20160346301A1 (en) 2016-12-01
CA2987272A1 (en) 2016-12-01
US9949990B2 (en) 2018-04-24
US9795620B2 (en) 2017-10-24
US20180200270A1 (en) 2018-07-19
EP3302429A1 (en) 2018-04-11
BR112017025445A2 (pt) 2018-08-07
NZ737561A (en) 2019-08-30
KR20180012277A (ko) 2018-02-05
US10799517B2 (en) 2020-10-13
AU2019203815A1 (en) 2019-06-20
AU2016267685A1 (en) 2017-12-07
CN114209707A (zh) 2022-03-22
JP2018516266A (ja) 2018-06-21
CN117547528A (zh) 2024-02-13
US20180200271A1 (en) 2018-07-19
MX2017015238A (es) 2018-02-19
RU2017144574A3 (enExample) 2019-07-17
WO2016191744A1 (en) 2016-12-01
EA201792530A1 (ru) 2018-10-31
CN107847437A (zh) 2018-03-27
RU2708254C2 (ru) 2019-12-05
MX384044B (es) 2025-03-14
WO2016191744A8 (en) 2018-01-25
EA038013B1 (ru) 2021-06-23
US20180008619A1 (en) 2018-01-11
CA2987272C (en) 2019-08-20
US20170119798A1 (en) 2017-05-04
US9572819B2 (en) 2017-02-21

Similar Documents

Publication Publication Date Title
KR101994129B1 (ko) 통증 치료를 위한 셀레콕시브 경구용 조성물
US20250127714A1 (en) Oral composition of celecoxib for treatment of pain
US9511078B2 (en) Self-nanoemulsion of poorly soluble drugs
Song et al. Novel luteolin@ pro-phytomicelles: In vitro characterization and in vivo evaluation of protection against drug-induced hepatotoxicity
KR20150112975A (ko) 경구 및 비경구적 전달을 위한 클로피도그렐 유리 염기의 안정한 약학 조성물
CN107921017A (zh) 使用卡多曲组合物进行治疗的方法
RU2795918C1 (ru) Пероральная композиция целекоксиба для лечения боли
RU2765946C1 (ru) Система доставки сверхнасыщаемых самонаноэмульгирующихся лекарственных средств (SNEDDS) для слаборастворимых в воде фармацевтических композиций и способ ее приготовления
BR112017025445B1 (pt) Composição oral de celecoxibe para tratamento da dor
CN117715623A (zh) 恩杂鲁胺的新型口服液组合物及其制备方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171213

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180426

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20180426

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180702

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190125

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180702

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190125

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20181128

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20180426

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20190322

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20190225

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190125

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20181128

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20180426

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190624

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190625

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20220622

Start annual number: 4

End annual number: 4